Bonaventura et al., 2019 - Google Patents
Cold tumors: a therapeutic challenge for immunotherapyBonaventura et al., 2019
View HTML- Document ID
- 2203919893519212776
- Author
- Bonaventura P
- Shekarian T
- Alcazer V
- Valladeau-Guilemond J
- Valsesia-Wittmann S
- Amigorena S
- Caux C
- Depil S
- Publication year
- Publication venue
- Frontiers in immunology
External Links
Snippet
Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the treatment landscape of many tumors. However, response rate remains relatively low in most cases. A major factor involved in initial resistance to ICP inhibitors is the lack or paucity of …
- 206010028980 Neoplasm 0 title abstract description 129
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonaventura et al. | Cold tumors: a therapeutic challenge for immunotherapy | |
| Bughda et al. | Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma | |
| Lei et al. | Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy | |
| Bald et al. | The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Vanichapol et al. | Immune escape mechanisms and future prospects for immunotherapy in neuroblastoma | |
| Zeltsman et al. | CAR T-cell therapy for lung cancer and malignant pleural mesothelioma | |
| Muenst et al. | The immune system and cancer evasion strategies: therapeutic concepts | |
| Chester et al. | Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy | |
| Shiao et al. | The tumor-immune microenvironment and response to radiation therapy | |
| Long et al. | CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success | |
| Alghamri et al. | Targeting neuroinflammation in brain cancer: uncovering mechanisms, pharmacological targets, and neuropharmaceutical developments | |
| Multhoff et al. | The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation | |
| Jacobs et al. | Immune checkpoint modulation in colorectal cancer: what’s new and what to expect | |
| Wang et al. | Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications | |
| Escobar et al. | Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens | |
| Rahir et al. | Tumor microenvironment and lymphocyte infiltration | |
| Kwon et al. | Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy | |
| Dong et al. | Reprogramming immune cells for enhanced cancer immunotherapy: targets and strategies | |
| Mauge et al. | Control of the adaptive immune response by tumor vasculature | |
| Moretti et al. | THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside | |
| Chaudhary et al. | Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer | |
| Ascierto et al. | Melanoma: from incurable beast to a curable bet. The success of immunotherapy | |
| Zhou et al. | Chimeric antigen receptor T cells applied to solid tumors | |
| Wang et al. | Role of CD155/TIGIT in digestive cancers: promising cancer target for immunotherapy |